CDK4/6 inhibitors in Breast Cancer Therapy

Nyhet

Häftad, Engelska, 2026

Av Pankaj Kumar Singh, Manish K. Chourasia, Neelesh Kumar Mehra, Gowthamarajan Kuppusamy

2 539 kr

Kommande

CDK4/6 inhibitors in Breast Cancer Therapy examines the pivotal role of CDK4/6 inhibition in treating hormone receptor-positive (HR+)/HER2-negative advanced breast cancer. The book highlights FDA-approved applications of these inhibitors alongside endocrine therapy and explores ongoing research into their potential as neoadjuvant treatments. It provides insights into the drug discovery and development of CDK4/6 inhibitors, covering their molecular mechanisms, pharmacology, and clinical applications. The content addresses their use in mono and adjuvant therapies, as well as challenges in targeting, while also discussing market potential and post-marketing safety issues. This book is a valuable resource for researchers and academics, enhancing understanding of CDK4/6 inhibitors' chemistry and therapeutic implications. By presenting detailed information on clinical trials and market formulations, it equips the audience with essential knowledge to navigate the complexities of targeted breast cancer therapies and contributes to advancing research in this critical area.

Provides comprehensive insights into the drug discovery and development processes of CDK4/6 inhibitors, detailing their molecular mechanisms and pharmacological aspects relevant to targeted breast cancer therapy
Explores the current clinical applications of CDK4/6 inhibitors, including their use in mono and adjuvant therapies
Discusses the market potential and post-marketing safety issues associated with CDK4/6 inhibitors

Produktinformation

Utgivningsdatum2026-06-01
Mått191 x 235 x undefined mm
Vikt450 g
FormatHäftad
SpråkEngelska
Antal sidor330
FörlagElsevier Science
ISBN9780443446115

Tillhör följande kategorier

Farmakologi inom Medicin

Dr. Pankaj Kumar Singh, Ph.D., is an Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research-Hyderabad (NIPER-Hyderabad), India. He earned his Doctorate in Pharmaceutics from CSIR-Central Drug Research Institute, Lucknow. Dr. Singh is actively involved in various scientific and socially impactful projects funded by prestigious organizations, including TSCOST-DBT, CCRUM, DST, ICMR, and the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. Dr. Manish K. Chourasia, is currently working as a Senior Principal Scientist in the Division of Pharmaceutics and Pharmacokinetics at CSIR-Central Drug Research Institute (CDRI), Lucknow, a premium drug research institute in India. He received his PhD in Pharmaceutical Sciences from Dr. Harisingh Gour University, Madhya Pradesh, India and carried out his post-doctoral studies at Department of Pharmacy, National University of Singapore, Singapore. Having acquired valuable experience in both industry and academia, he subsequently joined the role of a scientist at CSIR-CDRI almost two decades ago. He has played a significant role in advancing the field of nanoparticle-based drug delivery for breast cancer, aiming to enhance the therapeutic outcome. He has published 80+ scientific papers including high-impact journal reviews. He has supervised more than 50 MS students and PhD students.Neelesh Kumar Mehra is an Assistant Professor of Pharmaceutics in the Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, India. He has authored more than 140 peer-reviewed publications in high-repute international journals, and has contributed to over 50 book chapters. He holds 4 granted patents and has 5 patent applications filed on manufacturing processes and compositions to improve therapeutic efficacy for drug delivery. He has supervised 5 PhD students and 36 MS students, and is currently guiding 10 PhD and 7 MS students on their dissertations and research projects. His research focuses on the design, development, and evaluation of ophthalmic nanoemulsions, liposomes, lipid-polymer nanoparticles, carbon nanoparticles, and chitosan/PLGA-lipid nanoparticles for drug and biomolecule delivery in biomedical applications. Dr. K. Gowthamarajan is a Professor & Head of the Department of Pharmaceutics at JSS College of Pharmacy, India. He holds a master’s (1996) and a Doctoral degree (2007) from Tamil Nadu Dr. MGR Medical University. With over 20 years in drug delivery research, he specializes in intranasal systems and personalized therapy. He has guided 50+ PG and 16 PhD students and secured various government research grants. An accomplished author with 150+ publications and 23 patents, he serves on multiple editorial boards and committees. He has received numerous awards, including the CV Raman International Fellowship.

1. CDK4/6 inhibitors: Drug discovery, development and classification2. CDK4/6 inhibitors: a medicinal chemistry, pharmacology, in-silico and drug delivery perspectives (SAR, LIGAND BINDING, SMALL MOLECULE, LIPINSKI RULE, PHYSICOCHEMICAL PROPERTIES)3. Molecular mechanism and mechanism of action of CDK4/6 inhibitors4. CDK4/6 inhibitors: clinical status, patent review and recent updates5. The neoteric paradigm of the use of CDK4/6 for breast cancer treatment as mono and adjuvant therapy6. The repurposing era of CDK4/6 in the treatment of various ailments7. Cytotoxic profile, molecular modelling, cell cycle arrest and apoptotic induction induced by CDK4/6 inhibitors8. The present-day means and challenges in the targeting of CDK4/6 inhibitors9. Market potential and post-marketing safety challenges of CDK4/6 inhibitors10. CDK4/6 inhibitors: future perspectives